Class / Patent application number | Description | Number of patent applications / Date published |
435600180 | Involving a nucleic acid encoding an enzyme | 56 |
20110143362 | METHOD FOR IDENTIFICATION OF PROTEASE ACTIVITY INHIBITORS AND ASSAYING THE PRESENCE OF PROTEASE ACTIVITY - A system for the identification of proteases and protease inhibitors is provided. The system has at least two components. The first component is a reporter construct with at least one binding site, a transcriptional promoter, an inducible promoter region, and at least one reporter gene, all functionally connected for expression of the reporter gene(s) in functional coordination with a transcriptional activation agent. The second component is a transcriptional activation agent comprising a nucleic acid binding domain, at least one protease substrate domain, and at least one transcriptional activation domain for an inducible promoter. The system allows detection and evaluation of agents affecting protease activity directed to the protease substrate domain. The system also allows for the detection of the presence of proteases in environmental samples. | 06-16-2011 |
20110151474 | METHOD OF ESTIMATING THE RISK OF EXPRESSION OF ADVERSE DRUG REACTION CAUSED BY THE ADMINISTRATION OF A COMPOUND, WHICH IS EITHER METABOLIZED PER SE BY UGT1A1 ENZYME OR WHOSE METABOLIC INTERMEDIATE IS METABOLIZED BY THE ENZYME - A method of estimating a risk of the expression of an adverse drug reaction caused by the administration of irinotecan, and a method of reducing the adverse drug reaction caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of UGT1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of an adverse drug reaction caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drub reaction, thereby reducing the adverse drug reaction caused by the administration of irinotecan. | 06-23-2011 |
20110165585 | MULTI-SPECIES POLYNUCLEOTIDE CONTROL SEQUENCES - The present invention relates to polynucleotide sequences which enable a polynucleotide control sequence, such as a promoter, to direct expression in a wide range of industrially relevant species, both prokaryotes and eukaryotes. When the polynucleotide sequences of the invention are applied in combination with selection marker genes it is possible to perform selectable cloning in a laboratory host and use the same construct in the final host | 07-07-2011 |
20110183349 | BIOMARKERS FOR IgA NEPHROPATHY AND APPLICATIONS THEREOF - The present invention provides a method for diagnosis or prognosis of IgA nephropathy in a subject based on detection of the expression level of one or more biomarker genes selected from the group consisting of thymosin β4 (Tmsb4), serine or cysteine proteinase inhibitor clade E member 2 (Serpine2), secreted phosphoprotein 1 (OPN), butyrophilin-like-2 (BTNL2), S100 calcium binding protein A8 (S100A8), Cystatin C (CysC), and any combination thereof. | 07-28-2011 |
20110183350 | METHOD FOR SELECTING SECONDARY NEUROSPHERE DERIVED FROM DIFFERENTIATED CELL-DERIVED PLURIPOTENT STEM CELL, CLONE SELECTED BY THE METHOD AND USE OF THE CLONE - In order to provide a therapeutic agent for nerve injury which contains iPS-derived neural stem cells and has low or no risk of side effects, as well as a method for treating a nerve injury using the iPS cells, by efficiently establishing in vivo the iPS-derived neural stem having low or no risk of tumor formation, neurospheres are formed following formation of embryoid bodies from the iPS cells, and a clone whose ratio of cells in which the promoter of Nanog gene is activated is 0.01% or less is selected, and the clone is administered to a patient suffering from the nerve injury. | 07-28-2011 |
20110189688 | GENES - The invention relates to mutations in B-Raf gene products. The mutations described are identified in human tumours of natural origin. These mutations are associated with cancerous phenotypes and can be used as a basis for the diagnosis of cancer, cancerous cells or a predisposition to cancer in human subjects, and the development of anti-cancer therapeutics. | 08-04-2011 |
20110212460 | ASSAY FOR NITROUS OXIDE NEUROLOGIC SYNDROME - A method for detection of susceptibility to nitrous oxide neurologic syndrome in a subject is disclosed. In one embodiment, the method comprises: (a) providing a sample from a subject, wherein said subject is a candidate for nitrous oxide anesthesia; and (b) detecting the presence or absence of folate, cobalamin, methionine and homocysteine pathway genetic polymorphisms in said sample, wherein the presence of a polymorphism indicates that the subject is susceptible to nitrous oxide neurologic syndrome. | 09-01-2011 |
20110223609 | Gene defects and mutant ALK kinase in human solid tumors - In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention. | 09-15-2011 |
20110223610 | Two secretory luciferases - The present invention is one gene construct or a combination of two gene constructs or expression vectors incorporating a | 09-15-2011 |
20110229906 | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS - This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), particularly treatment regimens including a protease inhibitor. The invention further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy using phenotypic or genotypic susceptibility assays. | 09-22-2011 |
20110244474 | Rapid screening of biologically active nucleases and isolation of nuclease-modified cells - Disclosed herein are methods and compositions for rapidly identifying active nucleases and cells having nuclease-mediated genomic modifications. | 10-06-2011 |
20110250610 | FERMENTIVE PRODUCTION OF ISOBUTANOL USING HIGHLY ACTIVE KETOL-ACID REDUCTOISOMERASE ENZYMES - Methods for the fermentative production of isobutanol is provided by the fermentative growth of a recombinant microorganism expressing a highly active ketol-acid reductoisomerase enzyme in addition to other enzymes required for conversion of glucose to isobutanol. | 10-13-2011 |
20110250611 | IMMUNOGLOBULIN DISPLAY VECTORS - Disclosed are mammalian expression vectors for expressing simultaneous expression of immunoglobulins as both a secreted and cell surface bound form. | 10-13-2011 |
20110262929 | ANTI-HS6ST2 ANTIBODIES AND USES THEREOF - The present invention provides antibodies that bind to HS6ST2 proteins, pharmaceutical compositions comprising the antibodies as active ingredients, methods for diagnosing cancer using the antibodies, HS6ST2 proteins conjugated to cytotoxic agents and pharmaceutical compositions comprising the HS6ST2 proteins as active ingredients. | 10-27-2011 |
20110262930 | Screening and Treatment Methods Using IGS5 Enzymes of the Metalloprotease Family - Polypeptides which are related to the neprilysin enzyme family and have zinc metalloprotease activities and are referred to as IGS5, polynucleotides encoding such polypeptides, vectors containing such polynucleotides, host cells containing such vectors, processes for producing such polypeptides and/or polynucleotides, screening methods for identifying compounds which stimulate or inhibit IGS5 polypeptides and/or polynucleotides, and the use of such polypeptides and/or polynucleotides in therapy of various dysfunctions, disorders or diseases, particularly cardiovascular diseases, metabolic diseases such as diabetes mellitus type II, and neurodegenerative disorders, such as Parkinson's Disease. | 10-27-2011 |
20110287440 | Composition and method for reconstituting IkB kinase in yeast and method of using same - The invention provides a means for reconstituting IκB kinase in yeast in order to study the structure and regulation of IKK and to produce pharmacological therapies to block IKK. This invention can be used to express an IKK complex that is biochemically identical to IKK isolated from native cells and in coupled in vitro kinase assays to screen for its upstream regulators. The IKK expressed by reconstituting the yeast can be used to screen for unknown substrates and for pharmacological therapies that block its activity. The invention could also be used to screen for compounds that enhance its activity. The IKK may also be used as a source of material for crystallization and X-ray diffraction analysis. | 11-24-2011 |
20120003662 | Methods and Kits for Detecting Mastitis - Methods and kits for determining if one or more animals have mastitis and for monitoring animals and the quality of the milk they produce are disclosed. Kits and test assays disclosed are used to determine the quantity of proteasomes and proteins thereof, the activity of proteasome enzymes, the quantity of proteasome bound and regulating proteins, and the quantity of ubiquinated protein. Components and reagents for use in the kits and assays are also disclosed. | 01-05-2012 |
20120077203 | REPORTER GENE CONSTRUCT, ASSAY KIT AND DETECTION METHOD - According to one embodiment, there is provided a reporter gene construct. The reporter gene construct comprises a transcriptional regulatory sequence and a reporter gene that is functionally bound to downstream of the transcriptional regulatory sequence. The reporter gene construct is activated dependently of environment and the reporter gene codes for a protein producible of producing a free radical by the | 03-29-2012 |
20120077204 | Detection of Protein Translocation by Beta-Galactosidase Reporter Fragment Complementation - Methods and compositions are provided for detecting molecular translocations, particularly protein translocations within and between sub-cellular compartments, using at least two components that exhibit a localization-dependent difference in complementation activity. In particular, alpha-complementing β-galactosidase fragments are provided. These β-galactosidase reporter fragments display significantly enhanced enzymatic activity when one fragment is localized in a membrane. Methods for carrying out no-wash ELISA assays based on the reporter component system are also provided. | 03-29-2012 |
20120100556 | Functional Expression of Higher Plant Nitrate Transporters in Pichia Pastoris - The present invention relates to a system for functional expression of higher plant nitrate transporter (Nrt) genes in | 04-26-2012 |
20120115158 | METHOD TO DETERMINE EMBRYO AND OOCYTE QUALITY BASED ON CERAMIDASE - The present invention relates to a method of predicting the likelihood of embryo or oocyte survival. This method involves providing a sample of an embryo, an oocyte, or surrounding liquid or cells, and screening the sample for ceramidase expression or activity. The ceramidase expression or activity obtained through said screening is then correlated to a prediction of the likelihood of embryo or oocyte survival. Also disclosed is a kit. | 05-10-2012 |
20120122113 | Signature Of Secreted Protein Isoforms Specific To Ovarian Cancer - The present invention relates to the identification of secreted protein isoforms specific in ovarian cancer and methods for diagnosis or prognosis of ovarian cancer in a subject by detecting the secreted protein isoforms. | 05-17-2012 |
20120171693 | Methods for Generating Novel Stabilized Proteins - The disclosure provides methods for identifying and producing stabilized chimeric proteins. | 07-05-2012 |
20120171694 | PREDICTIVE MARKERS AND BIOMARKER PANELS FOR OVARIAN CANCER - Methods are provided for predicting the presence, subtype and stage of ovarian cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. Associated test kits, computer and analytical systems as well as software and diagnostic models are also provided. | 07-05-2012 |
20120190038 | LovD MUTANTS EXHIBITING IMPROVED PROPERTIES TOWARDS SIMVASTATIN SYNTHESIS - The invention disclosed herein relates to methods and materials for producing simvastatin and related compounds such as huvastatin. In particular, the disclosure teaches that variants of the LovD acyltransferase polypeptide can be engineered to exhibit properties that facilitate their use in the production of simvastatin and/or huvastatin. The materials and processes disclosed herein are designed so that fermentation facilities currently producing lovastatin can be converted to producing simvastatin and related compounds with minimal modifications. | 07-26-2012 |
20120219959 | Targeted Chromosomal Mutagenesis Using Zinc Finger Nucleases - The present invention provides for a method or methods of targeted genetic recombination or mutagenesis in a host cell or organism, and compositions useful for carrying out the method. The targeting method of the present invention exploits endogenous cellular mechanisms for homologous recombination and repair of double stranded breaks in genetic material. The present invention provides numerous improvements over previous mutagenesis methods, such advantages include that the method is generally applicable to a wide variety of organisms, the method is targeted so that the disadvantages associated with random insertion of DNA into host genetic material are eliminated, and certain embodiments require relatively little manipulation of the host genetic material for success. Additionally, it provides a method that produces organisms with specific gene modifications in a short period of time. | 08-30-2012 |
20120322078 | Production of Propanols, Alcohols, and Polyols in Consolidated Bioprocessing Organisms - The present invention provides for novel metabolic pathways leading to propanol, alcohol or polyol formation in a consolidated bioprocessing system (CBP), where lignocellulosic biomass is efficiently converted to such products. More specifically, the invention provides for a recombinant microorganism, where the microorganism expresses one or more native and/or heterologous enzymes; where the one or more enzymes function in one or more engineered metabolic pathways to achieve: (1) conversion of a carbohydrate source to 1,2-propanediol, isopropropanol, ethanol and/or glycerol; (2) conversion of a carbohydrate source to n-propanol and isopropanol; (3) conversion of a carbohydrate source to isopropanol and methanol; or (4) conversion of a carbohydrate source to propanediol and acetone; wherein the one or more native and/or heterologous enzymes is activated, up-regulated or down-regulated. | 12-20-2012 |
20130089868 | Assay for Detection of Transient Intracellular CA2+ - This invention relates to a simple end point assay for detection of transient intracellular Ca | 04-11-2013 |
20130095497 | MICROORGANISM FOR QUANTIFYING HOMOCYSTEINE, AND USE THEREOF - Provided are a microorganism for use in quantification of homocysteine and methionine and a method of quantifying homocysteine and methionine in a sample by using the microorganism. | 04-18-2013 |
20130143227 | REGULATION OF WNT/BETA-CATENIN SIGNALING - A composition and method for detecting the ability of a compound to modulate the activity of LGR4, LGR5, or LGR6 receptors in a cell. LGR4, LGR5, and LGR6 are capable of activating the Wnt/β-catenin signaling system which plays essential roles in embryonic development and in the self-renewal and maintenance of adult stem cells. | 06-06-2013 |
20130171657 | RAPID SCREENING OF BIOLOGICALLY ACTIVE NUCLEASES AND ISOLATION OF NUCLEASE-MODIFIED CELLS - Disclosed herein are methods and compositions for rapidly identifying active nucleases and cells having nuclease-mediated genomic modifications. | 07-04-2013 |
20130210024 | COMBINATION TREATMENT OF CANCER - The present technology relates to a method of treating cancer by sensitizing human tumours to DNA damaging therapies through activating FBXO32 expression. Transactivation of FBXO32 through the inhibition of EZH2, a histone methyltransferase, decreases p21 protein induction which results in the sensitization of human tumours to chemotherapy. The method further provides a prognostic method to determine if a combination treatment would be effective. | 08-15-2013 |
20130224757 | INDUCED SPORULATION SCREENING METHOD - The present invention relates to a method of screening for an improved enzyme variant, said method comprising the steps of: (i) providing a recombinant host cell capable of sporulating comprising a polynucleotide encoding a sporulation factor and a polynucleotide encoding an enzyme variant which are operably linked to an inducible promoter; (ii) culturing the host cell under conditions suitable to induce the formation of spores; (iii) culturing the spores obtained in step (ii) in a medium containing a substrate for the enzyme variant; and (iv) determining the activity of the enzyme variant. | 08-29-2013 |
20130244245 | Orthogonal Translation Components for the in Vivo Incorporation of Unnatural Amino Acids - The invention relates to orthogonal pairs of tRNAs and aminoacyl-tRNA synthetase that can incorporate unnatural amino acid into proteins produced in eubacterial host cells such as | 09-19-2013 |
20130244246 | IMMORTALIZED AVIAN CELL LINES COMPRISING E1A NUCLEIC ACID SEQUENCES - This invention relates to immortalized avian cells, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans. | 09-19-2013 |
20130244247 | STRAINS OF SACCHAROMYCES CEREVISIAE - A method for producing a strain of | 09-19-2013 |
20130273554 | BIOLUMINESCENT PACKAGING - Some embodiments provided herein relate to bioluminescent packaging, methods of making, and methods of sensing the state of a material, in some embodiments, light emitted by a bioluminescent organism can be used to sense the state of a material. | 10-17-2013 |
20130273555 | Detoxification of Biomass Derived Acetate Via Metabolic Conversion to Ethanol, Acetone, Isopropanol, or Ethyl Acetate - One aspect of the invention relates to a genetically modified thermophilic or mesophilic microorganism, wherein a first native gene is partially, substantially, or completely deleted, silenced, inactivated, or down-regulated, which first native gene encodes a first native enzyme involved in the metabolic production of an organic acid or a salt thereof, thereby increasing the native ability of said thermophilic or mesophilic microorganism to produce lactate or acetate as a fermentation product. In certain embodiments, the aforementioned microorganism further comprises a first non-native gene, which first non-native gene encodes a first non-native enzyme involved in the metabolic production of lactate or acetate. Another aspect of the invention relates to a process for converting lignocellulosic biomass to lactate or acetate, comprising contacting lignocellulosic biomass with a genetically modified thermophilic or mesophilic microorganism. | 10-17-2013 |
20130280731 | RATIONAL ENZYME MINING - A method for rational mining for induced enzymes in microbial communities is described. The method is characterized in that a community of microorganisms is provided and that the microbial populations of the community are cultivated in a container under conditions of choice, where the microorganisms are given a defined culturing medium, to eliminate matter deriving from the natural habitat and to allow the microbial community to reach a metabolic steady-state. The method is further characterized in that at least one fraction of microorganisms is taken from the container and transferred into at least two separate containers, where at least one of the fractions of microorganisms is provided with a defined medium which includes an inducing substance and/or a substance against which enzyme/enzymes is/are desired, to induce regulation of expression of the desired enzyme/enzymes, and at least one fraction is provided with a defined medium without said inducing substance and without said substance against which enzyme/enzymes is/are desired, for the purpose of comparison, and the fractions are maintained and/or cultivated. Samples of the two fractions are then withdrawn and analyzed for identification of the induced enzyme/enzymes. | 10-24-2013 |
20130316364 | Selection Method and Recombinant Microorganisms and uses Therefor - One or more genes in a biosynthesis pathway for a vitamin or other essential nutrient which is needed for the survival of a microorganism can be used as an effective selective marker to identify cells transformed with an exogenous nucleic acid. The microorganism does not naturally contain or express the one or more gene. This permits genetic manipulations to be performed. It permits lower cost fermentations to be performed. It permits production of the essential nutrient for subsequent commodity use. | 11-28-2013 |
20140017696 | Measuring Subcellular Concentrations in Vivo - An isolated nucleic acid reporter construct, the protein for which it encodes and methods for its use for the in vivo or in vitro measurement of the concentration of a specific biologically important molecule in a subcellular compartment or locale are provided. Certain constructs described are useful in measuring the local concentration of ATP at synapses. | 01-16-2014 |
20140017697 | METHOD FOR IDENTIFICATION OF PROTEASE ACTIVITY INHIBITORS AND ASSAYING THE PRESENCE OF PROTEASE ACTIVITY - A system for the identification of proteases and protease inhibitors is provided. The system has at least two components. The first component is a reporter construct with at least one binding site, a transcriptional promoter, an inducible promoter region, and at least one reporter gene, all functionally connected for expression of the reporter gene(s) in functional coordination with a transcriptional activation agent. The second component is a transcriptional activation agent comprising a nucleic acid binding domain, at least one protease substrate domain, and at least one transcriptional activation domain for an inducible promoter. The system allows detection and evaluation of agents affecting protease activity directed to the protease substrate domain. The system also allows for the detection of the presence of proteases in environmental samples. | 01-16-2014 |
20140030730 | ACETYL-COA PRODUCING ENZYMES IN YEAST - The present invention relates to a method of identifying a heterologous polypeptide having enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA in (the cytosol of) a yeast cell comprising: a) providing a mutated yeast cell comprising a deletion of at least one gene of the (PDH) by-pass, selected from the genes encoding the enzymes pyruvate decarboxylase (PDC), acetaldehyde dehydrogenase (ALD), and acetyl-CoA synthetase (ACS); b) transforming said mutated yeast cell with an expression vector comprising a heterologous nucleotide sequence encoding a candidate polypeptide having potential enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA; c) testing said recombinant mutated yeast cell for its ability to grow on minimal medium containing glucose as sole carbon source, and d) identifying said candidate polypeptide as a heterologous polypeptide having enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA in (the cytosol of) said yeast cell when growth of said cell is observed. The invention further relates to a method of producing a fermentation production such as butanol. | 01-30-2014 |
20140051090 | APTAMER SENSOR DEVICE - The present invention relates to aptazyme sensor devices comprising, in addition to the aptamer, ribozyme and communication components, a competitive inhibitory component with a metal nanoparticle or a competitive inhibitory and signalling component with a metal nanoparticle and a label, such that the enzymatic activity of the ribozyme is inhibited as long as the inhibitory or the inhibitory and signalling component is bound to the substrate binding site of the ribozyme. The aptazyme sensor devices of the invention have increased shelf-life and are suitable for the parallel detection of different ligands by using an array of aptazyme sensor devices utilizing inhibitory and inhibitory and signalling components with different metal nanoparticles. The present invention furthermore relates to the post-synthetic chemical modification of the aptamer component for avoiding unspecific binding. | 02-20-2014 |
20140113304 | Bi-Directional Cytosine Deaminase-Encoding Selection Marker - The present invention relates to a bi-directional cytosine deaminase-encoding selection marker as well as methods for using said marker. | 04-24-2014 |
20140120548 | SYNTHETIC OPLOPHORUS LUCIFERASES WITH ENHANCED LIGHT OUTPUT - A polynucleotide encoding a modified luciferase polypeptide. The modified luciferase polypeptide has at least 60% amino acid sequence identity to a wild-type | 05-01-2014 |
20140141448 | NOVEL 2,5-DIKETO-L-GLUCONIC ACID REDUCTASES AND METHODS OF USE - Described herein are novel nucleic acids, proteins and methods that can be used to provide new catalysts with desirable traits for industrial processes. In particular, novel reductases isolated from the environment using PCR methods are described. | 05-22-2014 |
20140242600 | IMAGING THE HETEROGENEOUS UPTAKE OF RADIOLABELED MOLECULES IN SINGLE LIVING CELLS - A radioluminescence microscopy system and method for imaging the distribution of radiolabeled molecules in live cell cultures and tissue sections. Cells are grown and incubated with radiolabeled molecules on a scintillator plate or a scintillator plate is placed adjacent to the cells after incubation. Scintillation light produced by decay of radiolabeled molecules inside, bound to, or surrounding the cells, is recorded on an imaging device. Fluorescence microscopy of the same cells with other types of molecules of interest that are labeled with different fluorophores can be conducted concurrently and the biological activity of the labeled molecules can be correlated. | 08-28-2014 |
20140287426 | ANTIBODY AND ANTIBODY MIMETIC FOR VISUALIZATION AND ABLATION OF ENDOGENOUS PROTEINS - Provided are compositions and methods for labeling an endogenous protein, in particular, in a live cell, or for ablating an endogenous or target protein. The compositions relate to a fusion protein having a binding moiety such as an antibody, an antigen binding fragment of an antibody or an antibody mimetic that recognizes the endogenous or target protein. | 09-25-2014 |
20150291938 | FIREFLY LUCIFERASE - The present invention relates to a luciferase derived from a Malaysian | 10-15-2015 |
20150299715 | SENSOR FOR NADP (H) AND DEVELOPMENT OF ALCOHOL DEHYDROGENASES - The present invention relates to an NADP(H) nanosensor comprising
| 10-22-2015 |
20150299764 | IMMOBILISED CYCLIN-DEPENDENT KINASE 4 FUSION PROTEINS AND USES THEREOF - The present invention concerns an in vitro assay for determining the activation status of endogenous CDK4 in eukaryotic cells, said assay comprising the steps of: providing eukaryotic cells maintained in a quiescent state, said eukaryotic cells comprising a cyclin D/CDK4 fusion protein, wherein the CDK4 part of the fusion protein is present in a hypophosphorylated form; inducing proliferation of said eukaryotic cells; isolating the cyclin D/CDK4 fusion protein from said eukaryotic cells; and measuring the activation status of said isolated cyclin D/CDK4 fusion protein, thereby determining the activation stats of endogenous CDK4 in said eukaryotic cells. | 10-22-2015 |
20150315599 | Methods and Systems for Methylotrophic Production of Organic Compounds - The present disclosure identifies pathways, mechanisms, systems and methods to confer production of carbon-based products of interest, such as sugars, alcohols, chemicals, amino acids, polymers, fatty acids and their derivatives, hydrocarbons, isoprenoids, and intermediates thereof, in engineered and/or evolved methylotrophs such that these organisms efficiently convert C1 compounds, such as formate, formic acid, formaldehyde or methanol, to organic carbon-based products of interest, and in particular the use of organisms for the commercial production of various carbon-based products of interest. | 11-05-2015 |
20150316551 | Sumoylation of SERCA2a and Cardiovascular Disease - Methods for treating cardiovascular disease, and in particular heart failure, are provided comprising administering a therapeutically effective amount of a modulator of SERCA2a post-translation modification such as SUMOylation or acetylation. Also provided are methods of treating cardiovascular disease by inhibiting SERCA2a degradation. Further provided are methods of diagnosing a propensity to develop heart failure comprising determining if a SERCA2a mutant is present or determining the level of expression of SUMO1 in cardiomyocytes. The disclosure also provides methods of screening for therapeutics that modulate the post-translational modification of SERCA2a, such as by modulating post-translational SUMOylation and/or acetylation. | 11-05-2015 |
20160076079 | NOVEL LUCIFERASE SEQUENCES UTILIZING INFRARED-EMITTING SUBSTRATES TO PRODUCE ENHANCED LUMINESCENCE - Provided herein are isolated polynucleotide encoding modified click beetle luciferase polypeptides that have enhanced luminescence and longer wavelength near-infrared signals. The disclosure also relates to near-infrared bioluminescence systems that include said modified click beetle luciferase polypeptides and novel luciferin derivatives, as well as methods of using said modified click beetle luciferase polypeptides and bioluminescence systems. | 03-17-2016 |
20160186234 | CODON-OPTIMIZED GENE FOR MUTATED SHRIMP LUCIFERASE AND METHOD FOR USE THEREOF - There has been a demand for a codon-optimized gene for the mutated catalytic domain of | 06-30-2016 |